Haleon PLC ((GB:HLN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Haleon PLC is conducting a clinical study titled ‘A 12-Week Randomized, Controlled, Single-Blind, Clinical Study Investigating the Efficacy of an Experimental Toothpaste Containing Stannous Fluoride in Improving Gingival Health.’ The study aims to evaluate the effectiveness of a new toothpaste containing 0.454% Stannous Fluoride in enhancing gingival health and reducing plaque compared to a standard fluoride toothpaste in individuals with gingivitis.
The intervention being tested is an experimental toothpaste labeled as ‘Test Fluoride Toothpaste,’ which contains 0.454% Stannous Fluoride, 0.3% zinc chloride, and 1% alumina. This is compared against the ‘Colgate Cavity Protection Toothpaste,’ a regular fluoride toothpaste containing 0.76% sodium monofluorophosphate.
The study is designed as a randomized, controlled, single-blind trial with a parallel intervention model. The primary purpose is treatment, and the investigator is the masked party. Participants will use the assigned toothpaste twice daily for 12 weeks.
The study began on September 4, 2025, with the latest update submitted on September 16, 2025. These dates are crucial as they indicate the study’s current recruiting status and progress.
This study could influence Haleon’s market position by potentially introducing a new product that improves dental health, impacting investor sentiment positively. It also positions Haleon against competitors like Colgate, highlighting innovation in dental care solutions.
The study is ongoing, with further details available on the ClinicalTrials portal.